# Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

> **NCT03015792** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03015792
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-10
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-10-18
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Drug company decided to not fund the phase 2 portion
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015792, "Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03015792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*